Prothena Presents New Research in the Treatment of Alzheimer's Disease at Alzheimer's Association International Conference® 2023 (AAIC®)

Data from PRX012, PRX005 and PRX123 programs showcase promise of Prothena’s pipeline and commitment to transform the care of patients with Alzheimer's disease

Related Keywords

Netherlands ,Amsterdam ,Noord Holland ,Wagner Zago ,Prothena Corporation ,Exchange Commission ,Company On Twitter Prothenacorp ,Alzheimer Association International Conference ,Bristol Myers Squibb ,Nasdaq ,Association International ,Chief Scientific Officer ,Single Ascending Dose ,Humanized Monoclonal Antibody ,Single Ascending Dose Portion ,First In Human Double Blind ,Myers Squibb ,Study Results ,Binding Characteristics ,Potent Engagement ,Robust Clearance ,Surface Plasmon Resonance ,Quarterly Report ,Markets ,